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Copyright © 200? JCBN Summary Iron may induce oxidative stress via production of reactive oxygen species, facilitat-
ing mammary carcinogenesis. This study investigated the role of iron in relation to oxidative
stress as a potential risk factor in the development of breast cancer (BC). BC patients (n =1 2 1 )
and healthy age-matched controls (n = 149) were entered into the study. Iron and antioxidant
vitamins intakes were estimated using a quantitative food frequency questionnaire. Thirty one
subjects from each group provided blood samples for measurement of serum iron, plasma
malondialdehyde (MDA) and ferric reducing ability of plasma (FRAP). Total and non-heme
iron intake of BC patients were lower than those of the controls. However, the serum iron level
was significantly higher in BC patients. Plasma MDA levels were also significantly higher in
BC patients whereas no significant difference in FRAP values were observed between the two
groups. Log-transformed serum iron concentration showed no significant correlation with
MDA or FRAP. These results suggest that serum iron overload may be a breast cancer risk
factor possibly due to increased oxidative stress.
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Introduction
Breast cancer (BC) is the most prevalent form of cancer
among women worldwide. The rate of breast cancer is
increasing rapidly in East Asian countries where the
incidence had previously been low [1, 2]. Risk factors for
BC include family history, circulating levels of estrogen,
obesity, and certain diets. The increased consumption of
meat has been speculated to be a contributing factor to
excess iron intake which may facilitate cancer development
[3]. Iron is an essential micronutrient and the most abundant
transition metal in the human body. It plays a diversity of
important physiological functions to include oxygen trans-
port, energy production, and DNA synthesis [4, 5]. However,
as a transition metal, iron’s loosely bound electrons in its
outer shell facilitates the production of reactive oxygen
species (ROS), resulting in oxidative stress, DNA single
breaks, and oncogene activation [6, 7]. Interaction between
free radicals and polyunsaturated fatty acids in cell mem-
branes also induces lipid peroxidation, which may damage
the cell structure and function [8].
The accumulation of molecular damage has been linked to
various pathological conditions including carcinogenesis
[9]. Elevated DNA adducts as well as DNA strand breaks
have been found in aggressive breast tumors [10]. It has
been proposed that the conversion of estradiol to catechol
estrogen and semi-quinones may be a key process in breast
carcinogenesis [11]. Iron may reinforce estrogen-induced
carcinogenesis via accelerated production of ROS [12].
There has been research correlating the intake of heme
iron with BC risk [13]. Cade et al. reported that dietary iron
intake was inversely associated with breast cancer risk [14].
Others have found no association between dietary iron
intake and breast cancer [15–17]. Serum iron levels of
female who died of cancer have been shown to be signifi-
cantly higher than the level in control group [18]. No signif-
icant association between serum iron level and breast cancerY.-J. Bae et al.
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risk was found in prior reports [19–22]. This study investi-
gated the role of iron in relation to oxidative stress as a
possible risk factor in the development of breast cancer.
Materials and Methods
Subjects
The study involved 270 women aged 20–80 years. Breast
cancer patients (n = 121) and their age-matched controls
(n = 149) were recruited from Bundang Jesaeng General
Hospital or St. Vincent’s Hospital, Gyeonggi-do, South
Korea between 2006–2007. Breast cancer patients prior to
receiving any chemotherapy or radiotherapy were allowed
participation in the study. The number of patients classified
as stage 0, I, II, III and IV were 20, 41, 41, 15 and 4, respec-
tively (Table 1). Subjects with any history of liver diseases,
diabetes mellitus, respiratory disorders or cardiovascular
diseases were not included in the study. The study was
approved by the Institutional Review Board of the Bundang
Jesaeng General Hospital and St. Vincent’s Hospital in
South Korea.
Dietary assessment
Dietary intakes were assessed using a 100-item semi-
quantified food frequency questionnaire. Subjects completed
the interviewer-administered questionnaire on the average
frequency (daily, weekly, monthly, yearly or never) and
consumption (small- a half of the median size, median, and
large-1.5 times of the median size) of each food item. A
color photograph of the median sized food items were used
to improve the accuracy of portion size estimates. The food
frequency questionnaire was coded and analyzed by a
computer aided nutrient analysis program for professionals
(CAN-Pro 3.0, APAC Intelligence, Seoul, South Korea).
The intake of heme iron is calculated as 40% of the iron
supplied from MFP (meat, fish, poultry), while the re-
maining was calculated as non-heme iron [23, 24].
Blood analysis
Blood samples were taken from 31 age-matched members
of each group who agreed to donate. The samples were left
at room temperature for 30 min, centrifuged for 15 min at
2,500 rpm to separate the serum and plasma, and then stored
at −70°C. Serum iron concentrations were determined by
ICP-Atomic Emission Spectrometer (Vista-PRO, Varian,
Australia) after dissolution with nitric acid and H2O2 using a
microwave (Ethos touch control, Milestone Inc., Italy).
MDA (malondialdehyde) was measured in plasma based on
the method described by Yagi et al. [ 25]. FRAP (ferric
reducing ability of plasma) assay was carried out based
on the method described by Benzie and Strain [26].
Statistical analysis
All analyses were performed using the SASTM (version
Table 1. Anthropometric and lifestyle characteristics of the study subjects
Each value represents the Mean ± SD. BMI indicated body mass index. *Number of patients according to the
stage.
Control Cancer
t test 
(p value)
X2-test 
(p value)
Age (yrs) 49.27 ± 8.63 50.07 ± 9.30 0.466 —
Height (cm) 157.79 ± 4.86 156.71 ± 4.74 0.066 —
Weight (kg) 56.78 ± 6.83 58.28 ± 7.49 0.09 —
BMI (kg/m2) 22.83 ± 2.73 23.76 ± 2.92 p<0.01 —
Smoking
Current (%) 2.01 10.71 X2 = 9.7751
Former (%) 0.67 1.79 — (df = 2)
Never (%) 97.32 87.5 0.007
Drinking
Current (%) 44.3 48.21 X2 =1 . 2 1 1 0
Former (%) 0.67 1.79 — (df = 2)
Never (%) 55.03 50 0.545
Clinical Stage
0 20*
I4 1
II 41
III 15
IV 4Iron Status in Relation to Oxidative Stress in Breast Cancer
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9.1, SAS Inc., Cary, NC). The data were expressed as
means ± standard deviations (SD) and the significance of
differences between the patient and control group was
analyzed using the Student t test. Comparisons for general
characteristics and serum iron levels were analyzed using
the x2 test. The level of serum iron did not show a normal
distribution, and the log-transformed values were used for
statistical analysis. The associations between serum iron
and oxidative stress markers were determined by Pearson’s
correlation. The level of significance was set at p<0.05
unless otherwise stated.
Results
Anthropometric and lifestyle measures of the study-
subjects are shown in Table 1. The average age, height and
weight of BC patients were not significantly different from
those of the control subjects. However, the mean BMI of
cancer patients was significantly higher than that of the
control subjects (p<0.01). The patient group had a larger
proportion of subjects who were current smokers (p<0.01)
compared to their controls. No difference was observed in
alcohol intake habit.
Energy and antioxidant vitamins intakes are shown in
Table 2. The energy intake did not differ between the two
groups. The intakes of vitamin A (p<0.001),  β-carotene
(p<0.001), vitamin C (p<0.001) and vitamin E (p<0.01) in
the BC patients were significantly lower than those of the
control subjects. Table 3 compares dietary iron intake and
serum iron levels between BC patients and their counterparts.
The breast cancer group consumed significantly less total
iron (p<0.001) and non-heme iron (p<0.001) compared to
the control group. No difference was observed with heme
iron intake. However, the serum iron level and the propor-
tion of iron overloaded subjects were significantly higher in
BC patients compared to those of the control group (p<0.001
and p<0.05, respectively). The levels of plasma oxidative
stress markers are shown in Fig. 1. Plasma MDA level was
significantly higher in BC patients compared to that of the
control subjects (p<0.05). There was no significant differ-
ence in plasma levels of FRAP between the BC and control
group. Log-transformed serum iron concentrations showed
no significant correlation with either MDA or FRAP after
the values were adjusted for BMI and smoking status
(Fig. 2).
Discussion
To investigate iron as a possible risk factor in the develop-
ment of breast cancer in relation to excess oxidative stress,
we measured dietary intake and serum levels of iron, along
with blood oxidative stress markers in BC patients and their
healthy counterparts. Iron is an essential micronutrient to
maintain normal cell function. However, oxidative injuries
Table 2. Energy and antioxidant vitamin intakes of the breast cancer and control group
Each value represents the Mean ± SD.
Control Cancer
t test 
(p value)
Energy (kcal) 1898.00 ± 427.66 1911.58 ± 447.38 0.799
Vitamin A (ug RE) 924.77 ± 569.25 674.37 ± 318.05 p<0.001
Retinol 93.27 ± 56.29 100.13 ± 63.64 0.924
β-carotene 4564.86 ± 2805.73 3166.32 ± 1686.16 p<0.001
Vitamin C (mg) 159.76 ± 72.84 128.56 ± 61.91 p<0.001
Vitamin E (mg) 15.48 ± 6.59 13.20 ± 6.26 p<0.01
Table 3. Dietary iron intake and the level of serum iron of the breast cancer and control group
Each value represents the Mean ± SD.
Control Cancer
t test 
(p value)
X2-test 
(p value)
Iron intake (mg) 15.22 ± 4.70 13.27 ± 4.14 p<0.001 —
Heme iron 0.45 ± 0.26 0.46 ± 0.30 0.591 —
Non-heme iron 14.84 ± 4.64 12.8 ± 4.02 p<0.001 —
Serum iron (mg/L) 1.71 ± 0.43 3.03 ± 1.87 p<0.001
Iron overload (%) 45.16 70.97 — X2 =4 . 2 3 9 3
Normal (%) 54.84 29.03 (df = 1) 0.039Y.-J. Bae et al.
J. Clin. Biochem. Nutr.
358
as a consequence of excess local iron accumulation within
the breast have been postulated as a risk factor in breast
carcinogenesis [27]. Excessive intake of iron may predis-
pose to mammary carcinogenesis due to the fact that free
iron works as a catalyst for ROS generation [12]. However,
study results on the relationship between dietary iron intake
and breast cancer are not consistent. Epidemiological studies
have reported that there is no association between dietary
iron intake and BC risk [16, 17]. Lee et al. also found no
overall association between dietary intake of total iron or
heme iron with breast cancer [28]. However, a positive
association of both iron and heme iron intake with breast
cancer risk among women who consumed greater than 20
grams of alcohol per day was found indicating iron as a
possible confounding risk factor of breast cancer [28]. A
large scale study conducted in 3,452 Chinese female BC
patients reported that the intake of heme iron increased the
risk of breast cancer [13].
In the present study, the intake of total and non-heme iron
was significantly lower in BC patients compared to the
control subjects, while the level of serum iron in BC patients
was higher than that of the control subjects. The efficiency
of iron absorption is influenced by various factors including
the dietary source of iron and body iron storage. The intake
of non-heme iron consisted more than 95% of total iron
intake in both groups. Due to the low bioavailability of
non-heme iron, it is thought that the difference of non-heme
iron intake between the breast cancer patients and control
subjects did not largely affect the level of serum iron.
Results from this study also indicated that a significantly
higher proportion of the cancer patients (71.0%) were iron
overloaded compared to the control group (45.2%).
NHANES II data showed that the average serum iron level
of 3,244 BC patients was significantly higher than that of
their control [18]. The authors suggested that the relative
risk of developing cancer increases by 66% as the concentra-
tion of iron increases by 100 μg/dl. Iron-induced oxidative
stress may leads to one of two consequences: (1) redox
regulation failure that results into lipid peroxidation and
oxidative DNA damage, or (2) redox regulation that facili-
tates a variety of reducing and oxidative stress-protective
mechanisms through signal transduction. Both consequences
appear to be essential for iron-induced carcinogenesis.
Iron may facilitate estrogen-induced carcinogenesis via
accelerated production of ROS and induce oxidative stress
from redox regulation failure [12].
The most common parameters of oxidative stress include
blood levels of antioxidants, lipid peroxides and other oxi-
dized biomolecules [29–31]. We measured plasma MDA
concentrations as a representative for lipid peroxides and
FRAP as a marker of oxidative stress levels in plasma.
Results indicated that MDA levels were significantly higher
Fig. 1. The level of plasma MDA (a) and FRAP (b) of the
breast cancer and control group. *p<0.05; Significance
between cancer and control as determined by Student’s
t test.
Fig. 2. Correlations between log-transformed serum iron and
plasma MDA (a) and FRAP (b). NS; Not significant.Iron Status in Relation to Oxidative Stress in Breast Cancer
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in BC patients. Although the FRAP value was slightly
higher in cancer patients, no statistical significance was
observed.
Previous studies have found that breast cancer patients
have higher levels of plasma MDA compared to their
healthy controls [19, 32, 33]. Women with mammographic
dysplasia also displayed increased levels of urinary MDA
[34]. The increased circulating level of oxidized lipid
products such as MDA may derive from the lower intakes of
antioxidant nutrients such as vitamin A, β-carotene, vitamin
C, vitamin E, and/or higher level of oxidative stress such as
serum iron overload as observed in this study. The elevated
level of iron may serve as a stimulator to produce lipid
peroxides [35–37]. Iron has been implicated as having a
major role in the development of cardiovascular complica-
tions by acting as a catalyst to produce oxidized lipid
molecules including oxLDL [35]. Renal lipid peroxidation
was also observed in animals treated with ferric nitorilot-
riacetate, a known renal carcinogen [36, 37].
Iron has been indicated as a tumor associated factor in
breast carcinogenesis [12]. Ferritin, the iron storage protein,
has been shown to be increased in breast tumor tissues [38]
indicating there is an increased need for iron availability in
breast cancer development. Iron was also found significantly
higher in breast tumor tissue compared to normal tissue
although it is not clear whether iron overload is a cause or a
consequence of carcinogenesis [39]. The authors suggested
that pathological accumulation of iron in breast tissues
may be closely related to the development of breast cancer.
Mechanistic studies showed that circulating estrogen
facilitated iron release from ferritin storage, which contri-
butes to cancer initiation [40]. Based on these results, it is
speculated that higher serum levels of iron may be partly
associated with oxidative stresses found in breast cancer
patients. Although iron overload-induced increases in oxida-
tive stress has been explained to facilitate tumor formation
by regulating cell signaling processes that control prolifera-
tion and apoptosis [41], there is no evidence to show
carcinogenesis itself can accumulate more iron in breast
tissue or women who tends to accumulate more iron in their
body have higher risk of breast cancer. No significant
associations between serum iron and oxidative stress
markers were found. The level of oxidative stress is related
to the imbalance between the production of ROS and the
antioxidant capability, and iron is one of many factors
regulating oxidation-reduction homeostasis. Therefore, in
addition to iron, other factors are involved in the mainte-
nance of the oxidation-reduction balance. Our small sample
size and limited number of markers may have decreased the
power to detect a significant association between serum iron
and oxidative stress markers. In conclusion, serum iron
overload may be related to breast cancer risk possibly
secondary to increased oxidative stress. A lack of consis-
tency among different markers advocates for further studies
to elucidate factors that contribute to oxidative stress and
breast tumor development.
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